Department of Otorhinolaryngology, Head and Neck Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
Head Neck. 2013 Jun;35(6):858-67. doi: 10.1002/hed.23054. Epub 2012 Jun 19.
Combinations of genetic polymorphisms in biotransformation enzymes might modify the individual risk for head and neck cancer.
Blood from 432 patients with head and neck cancer and 437 controls was investigated for genetic polymorphisms in 9 different phase I and II biotransformation enzymes. Analysis of the risk-modifying effect was performed according to predicted enzyme activities, based on genetic polymorphisms in the corresponding genes.
Combination of polymorphisms in COX-2 or EPHX1 with high activity polymorphisms in UGT1A1, UGT1A6, or UGT1A7 showed a risk-modulating effect in head and neck carcinogenesis, especially among heavy smokers and patients with laryngeal cancer. However, no additional effect for the combination of these polymorphisms was discovered when compared to the impact of polymorphism in UGT1A1, UGT1A6, and UGT1A7 individually.
Predicted high activity polymorphisms in the phase II enzymes UGT1A1, UGT1A6, and UGT1A7 are associated with an increased risk of head and neck cancer.
生物转化酶中的遗传多态性组合可能会改变个体患头颈部癌症的风险。
对 432 例头颈部癌症患者和 437 例对照者的血液进行了 9 种不同的 I 相和 II 相生物转化酶的遗传多态性研究。根据相应基因中的遗传多态性，基于预测的酶活性，对头颈部癌变的风险修饰作用进行了分析。
COX-2 或 EPHX1 中的多态性与 UGT1A1、UGT1A6 或 UGT1A7 中的高活性多态性相结合，对头颈部致癌作用具有风险调节作用，尤其是在重度吸烟者和喉癌患者中。然而，与 UGT1A1、UGT1A6 和 UGT1A7 单独的多态性相比，这些多态性的组合并没有发现额外的影响。
II 相酶 UGT1A1、UGT1A6 和 UGT1A7 中预测的高活性多态性与头颈部癌症的风险增加有关。
